Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DX-DRG-C01
- Development stage
- Preclinical
- Lead developer
- Dx&Vx
- Modality
- Small Molecules, Peptides
01
Overview
DX-DRG-C01 is a Glucagon-like peptide 1 receptor (GLP-1R) agonist currently under development by Dx&Vx (formerly MG Med) for the treatment of obesity. The drug is designed to activate the GLP-1 receptor, mimicking the effects of the natural incretin hormone GLP-1, which plays a crucial role in appetite suppression and glucose-dependent insulin secretion. By targeting GLP-1R, DX-DRG-C01 aims to induce weight loss and improve metabolic health. It is positioned within the company's obesity treatment pipeline and is currently in the preclinical stage of development.
02
Targets
Beyond the preview
Go deeper on DX-DRG-C01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DX-DRG-C01.